1. Inicio
  2. Publicaciones
  3. Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia.

Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia.

Fecha de publicación: Fecha Ahead of Print:

Autores de INCLIVA

Grupos y Plataformas de I+D+i

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide and is the clinical manifestation of the atherosclerosis. Elevated LDL-cholesterol levels are the first line of therapy but the increasing prevalence in type 2 diabetes mellitus (T2DM) has positioned the cardiometabolic risk as the most relevant parameter for treatment. Therefore, the control of this risk, characterized by dyslipidemia, hypertension, obesity, and insulin resistance, has become a major goal in many experimental and clinical studies in the context of CVD. In the present review, we summarized experimental studies and clinical trials of recent anti-diabetic and lipid-lowering therapies targeted to reduce CVD. Specifically, incretin-based therapies, sodium-glucose co-transporter 2 inhibitors, and proprotein convertase subtilisin kexin 9 inactivating therapies are described. Moreover, the novel molecular mechanisms explaining the CVD protection of the drugs reviewed here indicate major effects on vascular cells, inflammatory cells, and cardiomyocytes, beyond their expected anti-diabetic and lipid-lowering control. The revealed key mechanism is a prevention of acute cardiovascular events by restraining atherosclerosis at early stages, with decreased leukocyte adhesion, recruitment, and foam cell formation, and increased plaque stability and diminished necrotic core in advanced plaques. These emergent cardiometabolic therapies have a promising future to reduce CVD burden.

Datos de la publicación

ISSN/ISSNe:
1661-6596, 1422-0067

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES  MDPI AG

Tipo:
Article
Páginas:
-
PubMed:
33440821

Citas Recibidas en Web of Science: 17

Documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • cardiometabolic risk; dipeptidyl peptidase 4; incretin system; proprotein convertase subtilisin kexin 9; sodium-glucose-co-transporter 2 inhibitors

Campos de Estudio

Financiación

Carlos III Health Institute
CONSELLERIA DE SANIDAD (2019/198C)
European Regional Development Fund (CB07/08/0043)
Generalitat Valenciana (GenT CDEI-04/20-B)
INSTITUTO SALUD CARLOS III (PI19/00169)

Proyectos y Estudios Clínicos

Role of the inflammatory processes in metabolic diseases and associated complications. Papel de los procesos inflamatorios en las enfermedades metabólicas y sus complicaciones asociadas.

Investigador Principal: HERMINIA GONZÁLEZ NAVARRO

PI19/00169 . INSTITUTO SALUD CARLOS III . 2020

CDEI-04/20-B BENT-T HERMINIA GONZALEZ (2019/198) CONTRATO

Investigador Principal: HERMINIA GONZÁLEZ NAVARRO

2019/198C . CONSELLERIA DE SANIDAD

Cita

Compartir